Dare Bioscience (DARE) Change in Account Payables (2013 - 2025)
Dare Bioscience's (DARE) quarterly Change in Account Payables came in at -$621272.0 in Q4 2025, down 252.59% YoY from $407154.0 in Q4 2024, and down 219.89% on a QoQ basis from $518208.0 in Q3 2025.
Dare Bioscience (DARE) Change in Account Payables (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 12 years of Change in Account Payables data on file, last reported at -$621272.0 in Q4 2025.
- Quarterly Change in Account Payables fell 252.59% year-over-year to -$621272.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$255146.0 (up 86.78% YoY) and the FY2025 annual result came in at -$255146.0, up 86.78% from the prior year.
- Change in Account Payables retreated to -$621272.0 in Q4 2025, from $518208.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $4.5 million in Q2 2023 to a low of -$1.7 million in Q2 2022.
- A 5-year average of $9439.7 and a median of -$31539.0 in 2025 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2021 — Change in Account Payables plunged 787.67% — and 2022, when it surged 506.37%.
- Tracing DARE's Change in Account Payables over 5 years: stood at $1.5 million in 2021, then tumbled by 196.79% to -$1.4 million in 2022, then retreated by 10.53% to -$1.6 million in 2023, then surged by 125.42% to $407154.0 in 2024, then plunged by 252.59% to -$621272.0 in 2025.
- The last three Change in Account Payables figures came in at -$621272.0 (Q4 2025), $518208.0 (Q3 2025), and -$120543.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -621,272.00 |
| Dec 31, 2025 | -621,272.00 |
| Sep 30, 2025 | 518,208.00 |
| Sep 30, 2025 | 518,208.00 |
| Jun 30, 2025 | -120,543.00 |
| Jun 30, 2025 | -120,543.00 |
| Mar 31, 2025 | -31,539.00 |
| Mar 31, 2025 | -31,539.00 |
| Dec 31, 2024 | 407,154.00 |
| Dec 31, 2024 | 407,154.00 |
| Sep 30, 2024 | -861,080.00 |
| Sep 30, 2024 | -861,080.00 |
| Jun 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.48 Mn |
| Mar 31, 2024 | 7,674.00 |
| Mar 31, 2024 | 7,674.00 |
| Dec 31, 2023 | -1.60 Mn |
| Dec 31, 2023 | -1.60 Mn |
| Sep 30, 2023 | -1.55 Mn |
| Sep 30, 2023 | -1.55 Mn |